Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jun;27(6):1049-53.
doi: 10.1007/s11095-010-0057-2. Epub 2010 Mar 3.

Bitter melon: antagonist to cancer

Affiliations
Review

Bitter melon: antagonist to cancer

Pratibha Nerurkar et al. Pharm Res. 2010 Jun.

Abstract

The incidence of cancer is increasing worldwide, in spite of substantial progress in the development of anti-cancer therapies. One approach to control cancer could be its prevention by diet, which inhibits one or more neoplastic events and reduces cancer risk. Dietary compounds offer great potential in the fight against cancer by inhibiting the carcinogenesis process through the regulation of cell homeostasis and cell-death machineries. For centuries, Ayurveda (Indian traditional medicine) has recommended the use of bitter melon (Momordica charantia) as a functional food to prevent and treat diabetes and associated complications. It is noteworthy to mention that bitter melon extract has no-to-low side effects in animals as well as in humans. The anti-tumor activity of bitter melon has recently begun to emerge. This review focuses on recent advancements in cancer chemopreventive and anti-cancer efficacy of bitter melon and its active constituents. Several groups of investigators have reported that treatment of bitter-melon-related products in a number of cancer cell lines induces cell cycle arrest and apoptosis without affecting normal cell growth. Therefore, the effect of bitter melon should be beneficial for health, and use of the non-modified dietary product is cost effective.

PubMed Disclaimer

References

    1. Am J Chin Med. 2002;30(2-3):195-205 - PubMed
    1. Cancer Res. 1983 Nov;43(11):5151-5 - PubMed
    1. CA Cancer J Clin. 2006 Sep-Oct;56(5):254-81; quiz 313-4 - PubMed
    1. Anticancer Res. 2000 Mar-Apr;20(2A):653-9 - PubMed
    1. Nat Rev Cancer. 2003 Oct;3(10):768-80 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources